The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese
- 16 November 2024
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 92, 106176
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 36 references indexed in Scilit:
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residenceMultiple Sclerosis and Related Disorders, 2021
- Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.Multiple Sclerosis and Related Disorders, 2021
- Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapyMultiple Sclerosis and Related Disorders, 2021
- Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibodyMultiple Sclerosis and Related Disorders, 2020
- Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment coursesAnnals of Neurology, 2015
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis OpticaJAMA Neurology, 2015
- Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis opticaJournal of Clinical Neuroscience, 2015
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Journal of Neurology, 2013
- Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis opticaJournal of Neurology, 2012